befotertinib + vorolanib

Befotertinib + vorolanib is a combination therapy consisting of a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and a multi-target anti-angiogenic TKI. Befotertinib (BPI-7711) selectively and irreversibly inhibits EGFR mutations, including the T790M resistance mutation and sensitizing mutations like L858R and Exon 19 deletions, while sparing wild-type EGFR. Vorolanib (CM082) is a small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit. Developed by Betta Pharmaceuticals, this combination is primarily investigated for the treatment of advanced non-small cell lung cancer (NSCLC) to potentially delay the onset of resistance and enhance anti-tumor efficacy by simultaneously blocking oncogenic signaling and tumor-associated angiogenesis.

Brand names

SaifeiFulaimei

Other names

BPI-7711 + CM082